Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, there was an error in the article
In the published article, the
Aasland, D., Götzinger, L., Hauck, L., Berte, N., Meyer, J., Effenberger, M., et al. (2019). Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR–CHK1, p21, and NF-κB.
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., et al. (2008). MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Jung, T. Y., Jung, S., Jin, S. G., Moon, K. S., Kim, I. Y., Kang, S. S., et al. (2009). The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Chen, S. H., Kuo, C. C., Li, C. F., Cheung, C. H. A., Tsou, T. C., Chiang, H. C., et al. (2015). O6-methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma.
Cohen, A. L., Holmen, S. L., and Colman, H. (2013). IDH1 and IDH2 mutations in gliomas.
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., et al. (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Falchook, G., Coleman, R. L., Roszak, A., Behbakht, K., Matulonis, U., Ray-Coquard, I., et al. (2019). Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial.
Falchook, G., Coleman, R. L., and Schilder, R. J. (2019). Paclitaxel and alisertib in recurrent ovarian cancer—in reply.
Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., De Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., et al. (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
Hong, X., O'Donnell, J. P., Salazar, C. R., Van Brocklyn, J. R., Barnett, K. D., Pearl, D. K., et al. (2014). The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Iwadate, Y., Matsutani, T. O. M. O. O., Hasegawa, Y., Shinozaki, N., Oide, T., Tanizawa, T., et al. (2010). Selection of chemotherapy for glioblastoma expressing O 6-methylguanine-DNA methyltransferase.
Jiang, P., Mukthavaram, R., Chao, Y., Nomura, N., Bharati, I. S., Fogal, V., et al. (2014).
Kaina, B., Christmann, M., Naumann, S., and Roos, W. P. (2007). MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
Kohsaka, S., Wang, L., Yachi, K., Mahabir, R., Narita, T., Itoh, T., et al. (2012). STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Lehman, N. L., O'Donnell, J. P., Whiteley, L. J., Stapp, R. T., Lehman, T. D., Roszka, K. M., et al. (2012). Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.
Louis, D. N., Aldape, K. D., Capper, D., Giannini, C., Horbinski, C. M., Ng, H. K., et al. (2021). ‘
Melguizo Alonso, C., Prados Salazar, J. C., Alvarez, P. J., Perazzoli, G., Oliver, J. A., López, R., et al. (2012). MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Okamoto, R., Takano, H., Okamura, T., Park, J. S., Tanimoto, K., Sekikawa, T., et al. (2002). O6-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
O'Shaughnessy, J., McIntyre, K., Wilks, S., Ma, L., Block, M., Andorsky, D., et al. (2021). Efficacy and safety of weekly paclitaxel with or without oral alisertib in patients with metastatic breast cancer: a randomized clinical trial.
Owonikoko, T. K., Niu, H., Nackaerts, K., Csoszi, T., Ostoros, G., Mark, Z., et al. (2020). Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses.
Poisson, M., Pereon, Y., Chiras, J., and Delattre, J. Y. (1991). Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA).
Sak, M., Zumbar, C. T., King, P. D., Li, X., Mifsud, C. S., Usubalieva, A., et al. (2019). Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
Sak, M., Williams, B. J., Zumbar, C. T., Teer, L., Al-Kawaaz, M. N., Kakar, A., et al. (2023). The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib
Stoyanov, G. S., Lyutfi, E., Georgieva, R., Georgiev, R., Dzhenkov, D. L., Petkova, L., et al. (2022). Reclassification of glioblastoma multiforme according to the 2021 World Health Organization classification of central nervous system tumors: a single institution report and practical significance.
Shi, J., Zhang, P., Dong, X., Yuan, J., Li, Y., Li, S., et al. (2023). METTL3 knockdown promotes temozolomide sensitivity of glioma stem cells via decreasing MGMT and APNG mRNA stability.
Stephen, Z. R., Kievit, F. M., Veiseh, O., Chiarelli, P. A., Fang, C., Wang, K., et al. (2014). Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6-benzylguanine to brain tumors.
Tanaka, S., Kobayashi, I., Utsuki, S., Oka, H., Yasui, Y., Fujii, K., et al. (2005). Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.
Uno, M., Oba-Shinjo, S. M., Camargo, A. A., Moura, R. P., de Aguiar, P. H., Cabrera, H. N., et al. (2011). Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
Van Brocklyn, J. R., Wojton, J., Meisen, W. H., Kellough, D. A., Ecsedy, J. A., Kaur, B., et al. (2014). Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.
Viel, T., Monfared, P., Schelhaas, S., Fricke, I. B., Kuhlmann, M. T., Fraefel, C., et al. (2013). Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
Westermark, B., Ponten, J., and Hugosson, R. (1973). Determinants for the establishment of permanent tissue culture lines from human gliomas.
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., Van Den Bent, M. J., Wick, W., et al. (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Zhao, Y., Xiao, A., Carpenter, J. E., Abdel-Fattah, R., Redpath, G. T., Lopes, M. B. S., et al. (2010). An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.
Zumbar, C. T., Usubalieva, A., King, P. D., Li, X., Mifsud, C. S., Dalton, H. M., et al. (2018). The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.
In the published article, there was an error in
“Thus MGMT KO in U1210 cells and MGMT KD in U1210, T98 and LN18 gliomas cells all decrease anchorage-independent clonogenicity in soft agar.”
The corrected sentence appears below:
“Thus, MGMT KO in U1242 cells and MGMT KD in U1242, T98, and LN18 gliomas cells all decrease anchorage-independent clonogenicity in soft agar.”
In the published article, affiliation 6 was erroneously omitted and the corresponding affiliation number was not added for author Norman L. Lehman. Affiliation 6 has now been added as below: “6. Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States”
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in anyway. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.